Madrigal Pharmaceuticals
MDGL
31 hedge funds and large institutions have $20.1M invested in Madrigal Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 7 closing their positions.
57% more capital invested
Capital invested by funds: $12.8M → $20.1M (+$7.28M)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
11.63% more ownership
Funds ownership: 0% → 11.63% (+12%)
0% more funds holding
Funds holding: 31 → 31 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$6.99M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.62M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.8M |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$173K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$6.42M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$332K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$208K |
| 4 |
Millennium Management
New York
|
-$205K |
| 5 |
Goldman Sachs
New York
|
-$153K |
MDGL Hedge Fund Activity: Q4 2016 in Review
31 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2016, worth a combined $20.1M — up 57% from $12.8M a quarter earlier.
Fund positioning in MDGL was balanced in Q4 2016: 7 funds opened new positions, 7 closed out, 6 added to existing stakes and 5 trimmed.
The largest buyer was Capital World Investors, opening a new position worth an estimated $6.99M. The largest seller was Caxton Corporation, exiting entirely with an estimated $6.42M sold.
- 31 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $20.1M of Madrigal Pharmaceuticals stock for Q4 2016, up 57% quarter-over-quarter.
- 7 funds opened new Madrigal Pharmaceuticals positions in Q4 2016 and 7 closed out, a net change of 0 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2016 was Capital World Investors, an estimated $6.99M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2016 was Caxton Corporation, an estimated $6.42M sold.
Based on aggregated 13F filings for Q4 2016.